- Home
- KXIN vs CVKD Comparison
KXIN vs CVKD Comparison
Compare KXIN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KXIN
- CVKD
- Stock Information
- Founded
- KXIN 2015
- CVKD 2022
- Country
- KXIN China
- CVKD United States
- Employees
- KXIN N/A
- CVKD N/A
- Industry
- KXIN Retail-Auto Dealers and Gas Stations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- KXIN Consumer Discretionary
- CVKD Health Care
- Exchange
- KXIN Nasdaq
- CVKD Nasdaq
- Market Cap
- KXIN 10.5M
- CVKD 17.1M
- IPO Year
- KXIN N/A
- CVKD 2023
- Fundamental
- Price
- KXIN $0.16
- CVKD $14.45
- Analyst Decision
- KXIN
- CVKD Strong Buy
- Analyst Count
- KXIN 0
- CVKD 2
- Target Price
- KXIN N/A
- CVKD $52.50
- AVG Volume (30 Days)
- KXIN 90.2M
- CVKD 59.6K
- Earning Date
- KXIN 01-01-0001
- CVKD 11-08-2024
- Dividend Yield
- KXIN N/A
- CVKD N/A
- EPS Growth
- KXIN N/A
- CVKD N/A
- EPS
- KXIN N/A
- CVKD N/A
- Revenue
- KXIN $12,679,000.00
- CVKD N/A
- Revenue This Year
- KXIN N/A
- CVKD N/A
- Revenue Next Year
- KXIN N/A
- CVKD N/A
- P/E Ratio
- KXIN N/A
- CVKD N/A
- Revenue Growth
- KXIN N/A
- CVKD N/A
- 52 Week Low
- KXIN $0.06
- CVKD $5.40
- 52 Week High
- KXIN $3.55
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- KXIN 49.05
- CVKD 56.80
- Support Level
- KXIN $0.16
- CVKD $11.19
- Resistance Level
- KXIN $0.19
- CVKD $17.95
- Average True Range (ATR)
- KXIN 0.07
- CVKD 1.37
- MACD
- KXIN -0.01
- CVKD 0.10
- Stochastic Oscillator
- KXIN 4.65
- CVKD 49.64
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company primarily generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.